ArticleBMJ open2024
Selective early medical treatment of the patent ductus arteriosus in extremely low gestational age infants: a pilot randomised controlled trial protocol (SMART-PDA).
Article in BMJ open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05011149 (Selective Early Medical Treatment of the Patent Ductus Arteriosus in Extremely Low Gestational Age Infants), which is not on this map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Selective Early Medical Treatment of the Patent Ductus Arteriosus in Extremely Low Gestational Age Infants: A Pilot Randomized Controlled Trial
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants.The Cochrane database of systematic reviews · 2025Pooled it
- Making sense of the evidence: designing randomised controlled trials for preterm infants with high-shunt volume patent ductus arteriosus.Archives of disease in childhood. Fetal and neonatal edition · 2026Review
- Risk-Guided Personalized Care to Prevent Bronchopulmonary Dysplasia: A Real-World Implementation Study.Journal of personalized medicine · 2026Article
- Reliability of two-dimensional versus M-mode echocardiography for left atrium/aortic diameter ratio and fractional shortening in extremely preterm infants.Pediatric research · 2026Article
- Beyond diameter: redefining echocardiography criteria in trials of early PDA therapy.Journal of perinatology : official journal of the California Perinatal Association · 2026Article
- Management of the patent ductus arteriosus among infants born at 23 to 32 weeks' gestation between 2011 to 2022: a report from in the Children's Hospitals Neonatal Consortium.Journal of perinatology : official journal of the California Perinatal Association · 2025Article
- Response to the letter.Journal of perinatology : official journal of the California Perinatal Association · 2025Article
- A Discourse on Percutaneous Closure of the Patent Ductus Arteriosus in Premature Neonates: Controversy, Remedy, or Paradox of Choice?CJC pediatric and congenital heart disease · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPatent ductus arteriosus (PDA) is the most common cardiovascular problem that develops in extremely preterm infants and is associated with poor clinical outcomes. Uncertainty exists on whether early pharmacotherapeutic treatment of a clinically symptomatic and echocardiography-confirmed haemodynamically significant PDA in extremely preterm infants improves outcomes. Given the wide variation in the approach to PDA treatment in this gestational age (GA) group, a randomised trial design is essential to address the question. Before embarking on a large RCT in this vulnerable population, it is important to establish the feasibility of such a trial. METHODS AND ANALYSIS: ETHICS AND DISSEMINATION: The study has been approved by the IWK Research Ethics Board (#1027298) and six additional participating sites. On the completion of the study, results will be presented at national and international meetings, published in peer-reviewed journals and incorporated into existing systematic reviews. TRIAL REGISTRATION NUMBER: NCT05011149 (WHO Trial Registration Data Set in Appendix A). PROTOCOL VERSION: Ver 7.2 (dated July 19, 2023).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.